Figure S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

Franziska Siegel; Stephan Siegel; Kristýna Kotýnková; Gizem Karsli Uzunbas; Daniel Korr; Haruna Tomono; Sawyer Andersen; D.R. Denney; Markus Berger; Volker Schulze; Timothy A. Lewis; Bethany Kaplan; Sven Golfier; Jérémie Mortier; Roman Christian Hillig; Ulf Boemer; Kirstin Petersen; Knut Eis; Sybil M. Genther Williams; Dominik Rüttinger; Andrew D. Cherniack; Herbert Ho-Fung Loong; Koichi Goto; Paolo Grassi; Matthew M. Meyerson; Heidi E. Greulich

doi:10.1158/2159-8290.31047118

Figure S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

2026 Open access

Read full text

Authors: Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas, Daniel Korr, Haruna Tomono, Sawyer Andersen, D.R. Denney, Markus Berger, Volker Schulze, Timothy A. Lewis, Bethany Kaplan

+14 more

Sven Golfier, Jérémie Mortier, Roman Christian Hillig, Ulf Boemer, Kirstin Petersen, Knut Eis, Sybil M. Genther Williams, Dominik Rüttinger, Andrew D. Cherniack, Herbert Ho-Fung Loong, Koichi Goto, Paolo Grassi, Matthew M. Meyerson, Heidi E. Greulich

DOI: 10.1158/2159-8290.31047118

Cited by: 0

Abstract

The binding mode of sevabertinib within the ATP binding site of wild-type EGFR from two different views

Fields of Study & Subjects

Lung Cancer Treatments and Mutations HER2/EGFR in Cancer Research Computational Drug Discovery Methods

Publication details

Publication date: 12 January 2026